Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 24:12:1046307.
doi: 10.3389/fonc.2022.1046307. eCollection 2022.

Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)

Clàudia Pla  1   2 , Marta Solans  3   4 , Alberto Ameijide  1   2 , Arantza Sanvisens  5   6 , Marià Carulla  1   2 , María Dolores Rojas  7 , María Araceli Alemán  7 , Isabel Sáez-Lloret  8 , Cristina Díaz-Del-Campo  9 , Ana Isabel Marcos-Navarro  10 , Leire Sainz-de-Aja  11 , Amaia Aizpurua-Atxega  11 , Arantza Lopez-de-Munain  11 , Maria-José Sánchez  4   12   13   14 , Josefina Perucha  15 , Paula Franch  16   17 , María-Dolores Chirlaque  4   18 , Marcela Guevara  4   19   20 , Jaume Galceran  1   2 , Susana Merino  21 , Rafael Marcos-Gragera  4   5   6   22 ; REDECAN working group
Collaborators, Affiliations

Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)

Clàudia Pla et al. Front Oncol. .

Abstract

Introduction: The aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN).

Materials and methods: Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013).

Results: LNs accounted for 69% (n=39,156) of all hematological malignancies (n=56,751) diagnosed during the period of study. Median age at diagnosis was 67 years (interquartile range (IQR) = 52-77). The overall ASIRe was 34.23 (95% confidence interval (CI): 33.89, 34.57) and showed a marked male predominance in almost all subtypes (global sex ratio = 1.45). During the study period, incidence trends of LNs remained stable (APC: 0.3; 95% CI: -0.1, 0.6), nevertheless some subtypes showed statistically significant variations, such as LNs NOS category (APC: -5.6; 95% CI: -6.8, -4.3). Around 17,926 new cases of LNs will be diagnosed in 2023 in Spain. Survival rates differed considerably across age-groups, while they were similar between men and women. Five- year NS was 62.81% (95% CI: 62.1, 63.52) for all LNs, and varied widely across LNs subtypes, ranging from 39.21% to 90.25%. NS for all LNs improved from the first period of diagnosis to the second one, being 61.57% (95% CI: 60.56, 62.61) in 2002-2007 and 64.17% (95% CI: 63.29, 65.07) in 2008-2013.

Conclusions: This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented.

Keywords: Spain; incidence; lymphoid neoplasms; population-based; survival; trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to sex. LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-cell neoplasms; NOS, not otherwise specified.
Figure 2
Figure 2
Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to age-group (0-14, 15-49, 50-69 and 70 or more). LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-celll neoplasms; NOS, not otherwise specified.
Figure 3
Figure 3
Estimates of 5-year net survival for patients with lymphoid neoplasms diagnosed in 2002-2013, in Spain, according to period of diagnosis (2002-2007 and 2008-2013). LN, Lymphoid neoplasm; HL, Hodgkin lymphoma; PLN, precursor lymphoid neoplasms; mature B, mature B-cell neoplasms; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; LL/WM, lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; PCN, plasma cell neoplasms; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; Burkitt, Burkitt lymphoma/leukemia; Mature T/NK, mature T-cell and NK-celll neoplasms; NOS, not otherwise specified.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood (2008) 112:4384–99. doi: 10.1182/blood-2008-07-077982 - DOI - PMC - PubMed
    1. Jaffe ES, Harris NL, Stein H, Wardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; (2001).
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. et al. World Health Organization Classification of Tumours of haematopoietic and lymphoid tissues. Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, editors. Lyon, France: IARC (2008).
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H,TJ, et al. . Classification of tumours of haematopoietic and lymphoid tissues. In: World health organization classification of tumours, 4th Edition, vol. Volume 2. . Lyon, France: IARC; (2016).